All AbMole products are for research use only, cannot be used for human consumption.
LY518674 is a potent and selective PPAR-alpha antagonist with EC50 of 42 nM for human PPARα. LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. LY518674 produced a dose-dependent increase in serum HDL-c, resulting in 208 +/- 15% elevation at optimum dose. In cultured hepatocytes, LY518674 produced 50% higher apoA-1 secretion, which was associated with increase in radiolabeled methionine incorporation in apoA-1.
| Molecular Weight | 409.48 |
| Formula | C23H27N3O4 |
| CAS Number | 425671-29-0 |
| Solubility (25°C) | DMSO ≥ 100 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PPAR Products |
|---|
| WY 14643 (Pirinixic Acid)
WY 14643 (Pirinixic Acid) is a potent and selective, peroxisome proliferator-activated receptor-α (PPARα) agonist. |
| GSK 3787
GSK3787 is an orally available selective peroxisome proliferator-activated receptor δ (PPARδ) antagonist (pIC50 = 6.6). |
| Ciprofibrate
Ciprofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist. |
| ZLN005
ZLN005 is a novel and potent small molecule PGC-1α transcriptional activator. |
| Bezafibrate
Bezafibrate is the first clinically tested dual and pan-PPAR co-agonism. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
